TrMab6 strongly induced complement-dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC) activities against Trop2-overexpression CHO-K1 (CHO/Trop2) and breast cancer cell lines (MCF7, MDAMB231, and MDAMB468) [64]. Here, TACSTD2 is linked to breast carcinoma.